Completed OBSERVATIONAL NCT04647981

Diagnostic Performance Evaluation Study of the Xpert® Bladder Cancer Monitor Test. (Xpert Bladder)

Diagnostic Performance Evaluation Study of the Xpert® Bladder Cancer Monitor Test in the Surveillance of Patients With Non-Invasive Bladder Urothelial Carcinoma.

Sponsor: Cepheid

Conditions Non-Invasive Bladder Papillary Urothelial Carcinoma, High Grade Non-Invasive Bladder Papillary Urothelial Carcinoma, Low Grade Non-Invasive Bladder Urothelial Carcinoma

Interventions Xpert® Bladder Cancer Monitor Test

Updated 4 times since 2021 Last updated: Feb 8, 2021 Started: May 22, 2019 Primary completion: Dec 15, 2020 Completion: Jan 2, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Non-Invasive Bladder Papillary Urothelial Carcinoma, High Grade and Non-Invasive Bladder Papillary Urothelial Carcinoma, Low Grade and is currently completed. Cepheid leads this study, which shows 4 recorded versions since 2019 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Mar 2021 — Jul 2024 [monthly]

Completed

Status: Recruiting → Completed
Jan 2021 — Mar 2021 [monthly]

Recruiting

First recorded

May 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cepheid
Clinique Beau Soleil
Team Languedoc Mutualité / Nouvelles technologies

Data source: Clinique Beau Soleil

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Montpellier, France